Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5364581 | 0.96 | TLR7 (0.47) | TLR7TLR8CNR2PIM1PIM3 | |
| SCHEMBL5113144 | 0.93 | TLR7 (0.48) | TLR7TLR8CNR2PIM1PIM3 | |
| SCHEMBL5364616 | 0.89 | TLR7 (0.48) | TLR7CNR2PIM1PIM3DYRK1A | |
| SCHEMBL15205345 | 0.88 | TLR7 (0.40) | TLR7TLR8 | |
| SCHEMBL15205343 | 0.88 | TLR7 (0.40) | TLR7TLR8 | |
| SCHEMBL5348805 | 0.87 | CNR2 (0.47) | CNR2PIM1PIM3DYRK1AIDO1 | |
| SCHEMBL1952878 | 0.86 | CNR2 (0.44) | TLR7CNR2PIM1PIM3DYRK1A | |
| SCHEMBL25962881 | 0.86 | TLR7 (0.49) | TLR7CNR2PIM1PIM3 | |
| SCHEMBL5106169 | 0.84 | TLR7 (0.40) | TLR7TLR8CNR2PIM1PIM3 | |
| SCHEMBL5365500 | 0.84 | MAPT (0.46) | TLR7CNR2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157453-B2 | Urea substituted imidazoquinolines | 3M INNOVATION PROPERTIES COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050131009-A1 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-06-16 | — | — | US | disclosed |
| US-6897221-B2 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-6784188-B2 | ADMINISTERING TO A MAMMAL 1H-IMIDAZO(4,5-C)QUINOLINE RING CONTAINING COMPOUND FOR THE TREATMENT OF DISEASES, INCLUDING VIRAL AND NEOPLSATIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20040167154-A1 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-26 | — | — | US | disclosed |
| US-20040019048-A1 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-29 | — | — | US | disclosed |
| US-6573273-B1 | Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain urea, thiourea, acylurea, or sulfonylurea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can | 3M INNOVATIVE PROPERTIES COMPANY | 2003-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167154-A1 | Urea substituted imidazoquinolines | IFNG, EIF2AK2, IRF3 | TLR7 35/4885TLR8 237/4885CNR2 2428/4885 |
| US-20040019048-A1 | Urea substituted imidazoquinolines | IFNG, EIF2AK2, IRF3 | TLR7 35/4885TLR8 237/4885CNR2 2428/4885 |
| US-20050131009-A1 | Urea substituted imidazoquinolines | IFNG, EIF2AK2, IRF3 | TLR7 35/4885TLR8 237/4885CNR2 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.